Background & Aims Accurate estimates for the contemporary burden of chronic liver disease
(CLD) are vital for setting clinical, research, and policy priorities. We aimed to review the …

The syndemic of hazardous alcohol consumption, opioid use, and obesity has led to
important changes in liver disease epidemiology that have exacerbated health disparities …

Primary biliary cholangitis (PBC) is a chronic cholestatic autoimmune liver disease
characterized by a destructive, small duct, and lymphocytic cholangitis, and marked by the …

Primary biliary cholangitis (PBC) is a chronic, cholestatic, autoimmune disease with a
variable progressive course. PBC can cause debilitating symptoms including fatigue and …

Primary biliary cholangitis (PBC) is an archetypal autoimmune disease. Chronic lymphocytic
cholangitis is associated with interface hepatitis, ductopenia, cholestasis, and progressive …

Up to 40% of patients with primary biliary cholangitis have an incomplete response to first-
line treatment with ursodeoxycholic acid. Obeticholic acid was approved by the US Food …

Aim Autoimmune liver diseases (AILD) including autoimmune hepatitis (AIH), primary biliary
cholangitis (PBC), and primary sclerosing cholangitis (PSC) impose a significant burden on …

Primary biliary cholangitis (PBC) is an autoimmune disease characterized by the destruction
of intrahepatic small bile ducts and the presence of antimitochondrial antibody (AMA) …

For decades Black patients have been underrepresented in clinical trials of new treatments.
In response, in 2015 the Food and Drug Administration (FDA) launched a five-year action …

Background & Aims Autoimmune hepatitis (AIH), primary biliary cholangitis (PBC), and
primary sclerosing cholangitis (PSC) are autoimmune liver diseases of unknown etiology …